Scherer Laboratory

• Corinna Kronenthaler
  PhD student, now SYNLAB Mannheim
• Ann-Kathrin Glosch
• Amina-Karolin Haddawi
  Master student
• Marta Hinz
  HiWi
• Dr. Thomas Meyer
  Clinician Scientist
• Dr. Jan Mitschke
  Postdoc, now iOMEDICO AG
• Ella Riegler
  cand. med.
• Dr. Silvia Waldeck
  PhD student, now Labor für Haematologie Mannheim

Present and previous funding:

• Wilhelm Sander-Stiftung
• Bundesministerium für Forschung, Technologie und Raumfahrt
• Deutsche Krebshilfe
• Jose Carreras Stiftung
• Deutsche Forschungsgemeinschaft (DFG)
• Else Kröner-Fesenius-Stiftung (EKFS)
• BioThera-Stiftung
• Deutsche Gesellschaft für Innere Medizin (DGIM)
• Fördergesellschaft Forschung Tumorbiologie
• ZPM – Zentrum für Personalisierte Medizin
• DKTK – Deutsches Konsortium für Translationale Krebsforschung
• Mertelsmann Foundation
• Forschungskommission Freiburg
• Invest BW Innovationsförderung
• Roche Sequencing Solutions
• Gilead

Internal collaborations:

• FREEZE-Biobank – Zentrum für Biobanking
• Prof. Dr. Dr. Heinz Wiendl, Klinik für Neurologie
• PD Dr. Rick Dersch, Klilnik für Neurologie
• Dr. Dr. Christian Keller, Klinik für Neurologie
• PD Dr. Roman Sankowski, Institut für Neuropathologie
• Dr. Nicolas Neidert, Klinik für Neurochirurgie
• PD Dr. Elisabeth Schorb, Klinik für Innere Medizin I
• PD Dr. Peter Reinacher, Abteilung Stereotaktische und Funktionelle Neurochirurgie
• Prof. Dr. Dr. Melanie Börries, Insitut für Bioinformatik und System-Medizin
• Prof. Dr. Marco Prinz, Institut für Neuropathologie
• Prof. Dr. Jürgen Finke, Klinik für Innere Medizin I
• PD Dr. Frank Meiß, Klinik für Dermatologie und Venerologie
• Dr. Dietmar Pfeifer, Klinik für Innere Medizin I
• Dr. Timo Volk, Klinik für Neurologie
   

External collaborations:

• Ash A. Alizadeh MD/PhD, Stanford University
• Stefan Alig, MD, Stanford University
• David M. Kurtz MD/PhD, Stanford University
• Prof. Dr. Gerald Illerhaus, Klinikum Stuttgart
• Prof. Dr. Nikolas von Bubnoff, Universitätsklinikum Lübeck
• PD Dr. Lorenz Thurner, Universitätsklinikum des Saarlandes, Homburg/Saar
• Prof. Dr. Björn Chapuy, Universitätsklinikum Göttingen
• Prof. Dr. Oliver Weigert, LMU Klinikum München
• Prof. Dr. Roland Schmitz, Universitätsklinikum Gießen
• PD Dr. Louisa von Baumgarten, LMU Klinikum München

*Equal contribution

1. Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphoma. 
   Kuehn JC, Miarka L, Sankowski R, Mutter J, Neidert NN, Grabis E, Zhang J, Klingler C, Hummel F, Ranganathan L, Bleul S, Lauer EM, Heiland DH, Müller K, Reinhardt HC, Dietrich S, Illerhaus G, von Baumgarten L, Alig S, Diehn M, Sajonz BEA, Beck J, Coenen VA, Prinz M, Schorb E, Alizadeh AA, Duyster J, Reinacher P, Scherer F. 
   HemaSphere. 2026

2. High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation versus non-myeloablative consolidation in Primary CNS Lymphoma: Results of the Randomized Phase III MATRix/IELSG43 trial. 
   Illerhaus G, Ferreri AJM, Wendler J, Binder M, Borchmann P, Hasenkamp J, Stilgenbauer S, Röth A, Egerer G, Ernst T, Weber T, Hertenstein B, Lenz G, Dreyling M, Möhle R, Kobbe G, Schmidt CA, Brunnberg U, Panse J, Heinicke T, Schroll S, Larsen TS, Thurner L, Pukrop T, Salwender H, Naumann R, Hess G, Kroschinsky FP, Blystad AK, Keller U, Pulczynski EJ, Bjerregård Pedersen M, Re F, Orsucci L, Pospiech L, La Rosée P, Deckert M, Ponzoni M, Gmehlin D, Backenstrass M, Jensch A, Valk E, Calimeri T, Kasenda B, Trepel M, Fricker H, Semenova I, Scherer F, von Gottberg P, Burger E, Grishina O, Hader C, Ihorst G, Finke J, Zucca E, and Schorb E. 
   Lancet. 2026 

3. The effect of ibrutinib on the myeloid cell compartment in CNS lymphoma. 
   Kuehn JC, Neidert NN, Zhang J, Mutter J, Alig S, Klingler C, Hummel F, Ranganathan L, Bleul S, Beck J, Prinz M, Diehn M, Alizadeh AA, Duyster J, Sankowski R, Heiland DH, Scherer F. 
   Leukemia. 2025

4.  Guiding clinical management of patients with CNS lymphomas by minimal-invasive detection of ctDNA in cerebrospinal fluid. 
   Weinschenk S, Philipp U, Kühn J, Mueller K, Fauser J, Boeckle D, Gebhard I, Hinz M, Neidert N, Bleul S, Lauer E, Mutter J, Alig S, Kurtz D, Finke J, Marks R, Diehn M, Alizadeh AA, Reinacher P, Wehrle J, Keller U, Wolf D, Kocher F, Chapuy B, Beck J, Prinz M, von Baumgarten L, Schorb E, Duyster J, Scherer F. 
   Leukemia. 2025

5. Intraoperative classification of CNS lymphoma and glioblastoma by AI-based analysis of Stimulated Raman Histology (SRH). 
   Scheffler P, Straehle J, El Rahal A, Erny D, Mizaikoff B, Vasilikos I, Prinz M, Coenen VA, Kühn J, Scherer F, Heiland DH, Schnell O, Roelz R, Beck J, Reinacher PC, and Neidert N. 
   Brain and Spine. 2025 

6. Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors. 
   Kuehn JC, Metzger P, Neidert N, Matysiak U, Gräßel L, Philipp U, Bleul S, Pauli T, Falkenstein J, Bertemes H, Cysar S, Hess ME, Frey AV, Duque-Afonso J, Schorb E, Machein M, Beck J, Schnell O, von Bubnoff N, Illert AL, Peters C, Brummer T, Prinz M, Miething C, Becker H, Lassmann S, Werner M, Börries M, Duyster J, Heiland DH, Sankowski R, Scherer F. 
   npj Precision Oncology. 2024

7. Advanced diffusion imaging reveals microstructural characteristics of primary CNS lymphoma, allowing differentiation from glioblastoma. 
   Württemberger U, Diebold M, Rau A, Akgün V, Becker L, Beck J, Reinacher PC, Taschner CA, Reisert M, Fehrenbacher L, Erny D, Scherer F, Hohenhaus M, Urbach H, and Demrath T. 
   Neuro-Oncology Advances. 2024

8. High-dose chemotherapy and autologous stem cell transplant in elderly and fit PCNSL patients – the prospective, single-arm, phase 2 MARTA study. 
   Schorb E, Isbell LK, Kerkhoff A, Mathas S, Braulke F, Egerer G, Röth A, Schliffke S, Borchmann P, Brunnberg U, Kroschinsky F, Möhle R, Rank A, Wellnitz D, Kasenda B, Pospiech L, Wendler J, Scherer F, Deckert M, Henkes E, von Gottberg P, Gmehlin D, Backenstrass M, Jensch A, Burger-Martin E, Grishina O, Fricker H, Malenica N, Orban A, Duyster J, Ihorst G, Finke J, and Illerhaus 
   Lancet Haematology. 2024 

9. Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure.
   Mozaffari Jovein M, Ihorst G, Duque-Afonso J, Wäsch R, Bertz H, Wehr C, Duyster J, Zeiser R, Finke J, Scherer F.
   Blood Cancer Journal. 2023
10. Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.
    Lauer EM, Riegler E, Mutter JA, Alig SK, Bleul S, Kuehn J, Ranganathan L, Klingler C, Demerath T, Würtemberger U, Rau A, Weiß J, Eisenblaetter M, Bamberg F, Prinz M, Finke J, Duyster J, Illerhaus G, Diehn M, Alizadeh AA, Schorb E, Reinacher PC, Scherer F.
    Neuro-Oncology. 2023
11. Tracing founder mutations in circulating and tumor-resident follicular lymphoma precursors.
    Schroers-Martin JG*, Soo J*, Brisou G*, Scherer F*, Kurtz DM, Sworder B, Khodadoust MS, Jin, MC, Bru A, Long Liu CL, Stehr H, Vineis P, Natkuman Y, Teras LR, Song JY, Nadel B*, Diehn M*, Roulland S*, Alizadeh AA*.
    Cancer Discovery. 2023
12. Clinical applications of circulating tumor DNA in central nervous system lymphoma.
    Foerster AK, Lauer EM, Scherer F.
    Seminars in Hematology. 2023. Review
13. Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas.
    Mutter JA*, Alig S*, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, Kühn J, Bleul S, Olsen M, Liu CL, Jin MC, Macaulay CW, Neidert N, Volk T, Eisenblaetter M, Rauer S, Heiland DH, Finke J, Duyster J, Wehrle J, Prinz M, Illerhaus G, Reinacher PC, Schorb E, Diehn M, Alizadeh AA, Scherer F. Journal of Clinical Oncology. 2023
14. Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – the randomized phase III PRIMA-CNS trial.
    Isbell LK, Uibeleisen R, Friedl A, Burger E, Dopatka T, Scherer F, Orban A, Lauer E, Malenica N, Semenova I, Vreden A, Valk E, Wendler J, Neumaier S, Fricker H, El Rabih AAH, Gloggengießer C, Hilbig D, Bleul S, Weis J, Gmehlin D, Backenstrass M, Wirtz S, Ihorst G, Finke J, Illerhaus G, Schorb E.
    BMC Cancer. 2023
15. Patient-derived xenograft mouse model to investigate tropism to the central nervous system and retina in primary and secondary nervous system lymphoma.
    Isbell LK, Tschuch C, Doostkam S, Waldeck S, Andrieux G, Shoumariyeh K, Lenhard D, Schaefer HE, Reinacher PC, Bartsch I, Pantic M, Vinnakota JM, Kakkassery V, Schorb E, Scherer F, Frey AV, Boerries M, Illerhaus G, Duyster J, Schueler J, von Bubnoff N.
    Neuropathology and Applied Neurobiology. 2023
16. Development of highly sensitive digital droplet PCR for detection of cKIT mutations in circulating free DNA mediating resistance to TKI treatment in gastrointestinal stromal tumor (GIST).
    Rassner M, Waldeck S, Follo M, Jilg S, Philipp U, Jolic M, Wehrle J, Jost PJ, Peschel C, Illert AL, Duyster J, Scherer F, von Bubnoff N.
    International Journal of Molecular Sciences. 2023
17. Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
    Mutter JA*, Alig SK*, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, Kühn J, Bleul S, Olsen M, Liu CL, Jin MC, Macaulay CW, Neidert N, Volk T, Eisenblaetter M, Rauer S, Heiland DH, Finke J, Duyster J, Wehrle J, Prinz M, Illerhaus G, Reinacher PC, Schorb E, Diehn M, Alizadeh AA, Scherer F.
    Journal of Clinical Oncology. 2023
18. Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
    Wendler J, Fox CP, Valk E, Steinheber C, Fricker H, Isbell LK, Neumaier S, Okosun J, Scherer F, Ihorst G, Cwynarski K, Schorb E, Illerhaus G.
    BMC Cancer. 2022
19. Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation. 
    Waterhouse M, Pennisi S, Pfeifer D, Scherer F, Zeiser R, Duyster J, Bertz H, Finke J, Duque-Afonso J.
    Cancers. 2022
20. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
    Lauer EM*, Mutter J*, Scherer F.
    Leukemia. 2022. Review
21. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. 
    Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Salié H, Vollmer L, Kuliesiute U, von Ehr J, Benotmane JK, Neidert N, Follo M, Scherer F, Goeldner JM, Behringer SP, Franco P, Khiat M, Zhang J, Hofmann UG, Fung C, Ricklefs FL, Lamszus K, Boerries M, Ku M, Beck J, Sankowski R, Schwabenland M, Prinz M, Schüller U, Killmer S, Bengsch B, Walch AK, Delev D, Schnell O, Heiland DH.
    Cancer Cell. 2022
22. A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin.
    Strüßmann T, Wäsch R, Scherer F, Mutter JA, Pfeifer D, Bartsch I, Giesler S, Graziani G, Duyster J, Finke J, Marks R.
    Leukemia & Lymphoma. 2022
23. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. 
    Ravi VM, Neidert N, Will P, Joseph K, Maier JP, Kückelhaus J, Vollmer L, Goeldner JM, Behringer SP, Scherer F, Boerries M, Follo M, Weiss T, Delev D, Kernbach J, Franco P, Schallner N, Dierks C, Carro MS, Hofmann UG, Fung C, Sankowski R, Prinz M, Beck J, Salié H, Bengsch B, Schnell O, Heiland DH.
    Nature Communications. 2022
24. Stringent Base Specific and Optimization-Free Multiplex Mediator Probe ddPCR for the Quantification of Point Mutations in Circulating Tumor DNA. 
    Schlenker F, Kipf E, Deuter M, Höffkes I, Lehnert M, Zengerle R, von Stetten F, Scherer F, Wehrle J, von Bubnoff N, Juelg P, Hutzenlaub T, Borst N.
    Cancers. 2021
25. Early assessment of circulating tumor DNA afgter curative intent resection predicts tumor recurrence in early-stage and locally advanced non-small cell lung cancer
    Waldeck S, Mitschke J, Wiesemann S, Rassner M, Andrieux G, Deuter M, Mutter J, Lüchtenborg A-M, Kottmann D, Titze L, Zeisel C, Jolic M, Philipp U, Lassmann S, Bronsert P, Greil C, Rawluk J, Becker H, Isbell L, Müller A, Doostkam S, Passlick B, Börries M, Duyster J, Wehrle J, Scherer F*, von Bubnoff N*
    Molecular Oncology. 2021
     
26. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
    Kurtz DM*, Soo J*, Ting Keh LC, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding E, Shahrokh Esfahani M, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, and Alizadeh AA.
    Nature Biotechnology. 2021
     
27. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma
    Alig S*, Macaulay CW*, Kurtz DM*, Dührsen U, Hüttmann A, Schmitz C, Jin MC, Sworder BJ, Garofalo A, Shahrokh Esfahani M, Nabet BY, Soo J, Scherer F, Craig AFM, Casasnovas O, Westin JR, Gaidano G, Rossi D, Roschewski M, Wilson WH, Meignan M, Diehn M, and Alizadeh AA.
    Journal of Clinical Oncology. 2021
     
28. Transitioning the molecular tumor board from proof of concept to clinical routine: a german single-center analysis
    Hoefflin R, Lazarou A, Hess ME, Reiser M, Wehrle J, Metzger P, Frey AV, Becker H, Aumann K, Berner K, Boeker M, Buettner N, Dierks C, Duque-Afonso J, Eisenblaetter M, Erbes T, Fritsch R, Ge IX, Geißler AL, Grabbert M, Heeg S, Heiland DH, Hettmer S, Kayser G, Keller A, Kleiber A, Kutilina A, Mehmed L, Meiss F, Poxleitner P, Rawluk J, Ruf J, Schäfer H, Scherer F, Shoumariyeh K, Tzschach A, Peters C, Brummer T, Werner M, Duyster J, Lassmann S, Miething C, Boerries M, Illert AL, and von Bubnoff N.
    Cancers. 2021
     
29. Longitudinal analysis of cell-free mutated KRAS and CA19-9 predicts survival following curative resection of pancreatic cancer
    Hussung S, Akhoundova D, Hipp J, Follo M, Klar RFU, Philipp U, Scherer F, von Bubnoff N, Duyster J, Boerries M, Wittel U, and Fritsch RM.
    BMC Cancer. 2021
     
30. Change is coming: Plan S from the early career scientist perspective
    Borges NM*, Kabanova A*, Scherer F*.
    HemaSphere. 2020
     
31. Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
    Waterhouse M, Pennisi S, Pfeifer D, Deuter M, von Bubnoff N, Scherer F, Strüssmann T, Wehr C, Duyster J, Bertz H, Finke J, Duque-Afonso J.
    Bone Marrow Transplant. 2020
     
32. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study
    Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, Fricker H, Finke J, Illerhaus G
    Blood Advances. 2020
     
33. Personalized treatment selection and disease monitoring using circulating tumor DNA profiling in real-world cancer patient management
    Wehrle J, Philipp U, Jolic M, Follo M, Hussung S, Waldeck S, Deuter M, Rassner M, Braune J, Rawluk J, Greil C, Waller CF, Becker H, Duque-Afonso J, Illert AL, Fritsch RM, Meiss F, Duyster J, von Bubnoff N*, Scherer F*
    Diagnostics. 2020
     
34. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: a retrospective single center analysis
    Lauer EM, Waterhouse M, Braig M, Mutter J, Bleul S, Duque-Afonso J, Duyster J, Marks R, Reinacher PC, Prinz M, Illerhaus G, Finke J, Schorb E, Scherer F
    British Journal of Haematology. 2020
     
35. Capturing tumor heterogeneity and clonal evolution by circulating tumor DNA profiling
    Scherer F
    Recent Results in Cancer Research. 2020. Review
     
36. Development and clinical validation of discriminatory multi-target digital droplet PCR assays for the detection of hot spot KRAS and NRAS mutations in cell-free DNA 
    Hussung S, Follo M, Klar RFU, Michalczyk S, Fritsch K, Nollmann F, Hipp J, Duyster J, Scherer F, von Bubnoff N, Boerries M, Wittel U, Fritsch RM
    The Journal of Molecular Diagnostics. 2020
     
37. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
    Kurtz DM*, Esfahani MS*, Scherer F*, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschweski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA
    Cell. 2019
     
38. Determining cell type abundance and expression from bulk tissues with digital cytometry
    Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, Alizadeh AA
    Nature Biotechnology. 2019
     
39. Age-Related gliosis promotes central nervous system lymphoma through CCL19-mediated tumor cell retention
    O’Connor T, Zhou X, Kosla J, Adili A, Beccaria MG, Kotsiliti E, Pfister D, Johlke AL, Sinha A, Sankowski R, Schick M, Lewis R, Dokalis N, Seubert B, Höchst B, Inverso D, Heide D, Zhang W, Weihrich P, Manske K, Wohlleber D, Anton M, Hoellein A, Seleznik G, Bremer J, Bleul S, Augustin HG, Scherer F, Koedel U, Weber A, Protzer U, Förster R, Wirth T, Aguzzi A, Meissner F, Prinz M, Baumann B, Höpken Ü, Knolle PA, von Baumgarten L, Keller U, Heikenwalder M
    Cancer Cell. 2019
     
40. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
    Kurtz DM*, Scherer F*, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Duehrsen U, Huttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA
    Journal of Clinical Oncology. 2018
     
41. High-throughput sequencing for noninvasive disease detection in hematologic malignancies
    Scherer F*, Kurtz DM*, Diehn M, Alizadeh AA
    Blood. 2017. Review
     
42. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
    Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW Jr, Alizadeh AA, Diehn M
    Cancer Discovery. 2017
     
43. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
    Scherer F*, Kurtz DM*, Newman AM*, Stehr H, Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, Visser BC, Poultsides GA, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder CA, Diehn M, Alizadeh AA
    Science Translational Medicine. 2016
     
44. Integrated digital error suppression for improved detection of circulating tumor DNA
    Newman AM*, Lovejoy AF*, Klass DM*, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, Zhou L, Carter JN, West RB, Sledge GW, Shrager JB, Loo BW Jr, Neal JW, Wakelee HA, Diehn M, Alizadeh AA
    Nature Biotechnology. 2016
     
45. Circulating tumor DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
    Chabon JJ*, Simmons AD*, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M
    Nature Communications. 2016
     
46. Selection patterns of B-cell receptors and the natural history of follicular lymphoma
    Scherer F, van der Burgt M, Kiełbasa SM, Bertinetti-Lapatki C, Dühren von Minden M, Mikesch K, Zirlik K, de Wreede L, Veelken H, Navarrete MA
    British Journal of Haematology. 2016
     
47. Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation
    Scherer F, Navarrete MA, Bertinetti-Lapatki C, Boehm J, Schmitt-Graeff A, Veelken H
    Leukemia & Lymphoma. 2016
     
48. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
    Kurtz DM*, Green MR*, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C, Keane C, Kihira S, Visser B, Callahan J, Kong KA, Faham M, Corbelli KS, Miklos D, Advani RH, Levy R, HIcks RJ, Hertzberg M, Ohgami RS, Gandhi MK, Diehn M, Alizadeh AA
    Blood. 2015
     
49. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia
    Duque-Afonso J*, Feng J*, Scherer F, Lin CH, Wong SH, Wang Z, Iwasaki M, Cleary ML
    The Journal of Clinical Investigation. 2015
     
50. Organocatalytic removal of formaldehyde adducts from RNA and DNA bases
    Karmakar S*, Harcourt EM*, Hewings DS*, Scherer F, Lovejoy AF, Kurtz DM, Ehrenschwender T, Barandun LJ, Roost C, Alizadeh AA, Kool ET
    Nature Chemistry. 2015

Complete list of published work:
https://scholar.google.com/citations?user=FNTqYSsAAAAJ&hl=de

2026

CRIION – Joachim Frank Prize 2026

2026

Highly Cited Researcher Cross-Field, Web of Science

2025

‘Exzellenzstipendium’, Else Kröner-Fresenius-Stiftung

2025

Highly Cited Researcher Cross-Field, Web of Science

2024

Publication prize 2024, Else Kröner-Fresenius-Stiftung

2022

Takeda Oncology Research Prize NSCLC (3^rd prize)

2022

Advanced Clinician Scientist Award, German Society of Internal Medicine (DGIM)

2021

Artur-Pappenheim Prize, German Society of Hematology and Medical Oncology

2021

Oral Presentation Plenary Session and Abstract Achievement Award, ASH Annual Meeting, Atlanta, USA

2019

EHA-ASH Translational Research Training in Hematology (TRTH) Award

2018

Clinician Scientist Award, German Society for Internal Medicine (DGIM)

2017

Eugen-Graetz Prize, University of Freiburg

2013

Research Fellowship, Deutsche Forschungsgemeinschaft (DFG)

2008

German National Academic Foundation Scholarship (Stipendiat der Deutschen Studienstiftung)

PD Dr. med. Florian Scherer
Principal Investigator
florian.scherer@uniklinik-freiburg.de
Phone: +49 761 270 34010

Universitätsklinikum Freiburg
Klinik für Innere Medizin I
Hämatologie/Onkologie
Hugstetter Straße 55
D-79106 Freiburg

Mail Address:
Universitätsklinikum Freiburg
Hugstetter Straße 55
D-79106 Freiburg
Germany

Shipping/Deliveries:
Universitätsklinikum Freiburg
Zentrum Translationale Zellforschung (ZTZ), 3. OG
AG Scherer
Breisacher Straße 115
D-79106 Freiburg
Germany

Phone Laboratory:
+49 761 270 71870